↓ Skip to main content

Targeted drugs and Psycho-oncological intervention for breast cancer patients

Overview of attention for article published in Journal of Negative Results in BioMedicine, April 2016
Altmetric Badge

Mentioned by

twitter
3 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeted drugs and Psycho-oncological intervention for breast cancer patients
Published in
Journal of Negative Results in BioMedicine, April 2016
DOI 10.1186/s12952-016-0049-9
Pubmed ID
Authors

Flavio D’Abramo, Ute Goerling, Cecilia Guastadisegni

Abstract

Personalized medicine is a new field based on molecular biology and genomics in which targeted tumor therapies are administered to patients. Psycho-oncology is a complementary approach that considers social and psychological aspects of patients as part of the treatments for cancer patients.The aim of this mini-review is to weigh clinical benefits for breast cancer patients of both treatments and possibily enhance benefits by modulating the use of both interventions. We have compared and evaluated on the one hand the use of anti Vascular Endothelial Growth Factor and, on the other hand, psycho-oncological interventions in metastatic and non-metastatic breast cancer patients.Both treatments did not increase survival of metastatic breast cancer patients, while in a selected study psycho-oncological interventions extended lifespan of non-metastatic breast cancer patients and ameliorate psychological and social factors of metastatic breast cancer patients. Because the two approaches address completely different aspects of cancer patients, if the comparison is limited to the extension of survival, the value of these two treatments cannot be assessed and compared.It is likely that by comparing patients reported outcomes, possibly by using standardized Quality of Life questionnaires, both patients and health care providers can weigh the benefits of the two treatments. It is therefore important to evaluate the use of cancer patients' quality of life measures as a mean to improve their experiences about life and treatment, and possibly to extend their survival.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 22%
Student > Bachelor 4 10%
Student > Master 3 7%
Student > Postgraduate 3 7%
Other 2 5%
Other 5 12%
Unknown 15 37%
Readers by discipline Count As %
Medicine and Dentistry 9 22%
Psychology 4 10%
Nursing and Health Professions 4 10%
Agricultural and Biological Sciences 2 5%
Linguistics 1 2%
Other 5 12%
Unknown 16 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2016.
All research outputs
#17,795,140
of 22,858,915 outputs
Outputs from Journal of Negative Results in BioMedicine
#75
of 112 outputs
Outputs of similar age
#205,825
of 300,229 outputs
Outputs of similar age from Journal of Negative Results in BioMedicine
#3
of 4 outputs
Altmetric has tracked 22,858,915 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 112 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,229 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.